Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Origin Enterprises Plc Board/Management Information 2018

Oct 1, 2018

1973_rns_2018-10-01_03a0e0f6-fa54-48d4-8433-328b8643a995.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5966C

Origin Enterprises Plc

01 October 2018

Directorate Update

1 October 2018

Origin Enterprises plc ('Origin' or the 'Company') announces the appointment of Sean Coyle (45) to the Board of the Company with effect from today 1 October 2018, as previously outlined in the regulatory announcements of 7 June 2018 and 26 September 2018. Sean was appointed Chief Financial Officer on 1 September 2018.

Full details of his current and past directorships within the last five years are outlined below.  None of these entities have any relationship with Origin Enterprises plc.

There are no other items requiring disclosure in accordance with Schedule 2(g) of the AIM Rules for Companies or the ESM Rules for Companies. Sean Coyle currently has an interest in 7,000 ordinary shares in Origin.

Current Directorships

None

Past Directorships

Sean Gerard Coyle was a director or partner of the following within the last five years:

Steel Eagle Holdings, Inc
Dull Investment Corporation
Sharp Clinical Services Incorporated
Sharp Corporation
Ashfield Healthcare Communications, LLC
Ballina Pharma Inc
Magna Healthcare Inc
Ashfield Healthcare LLC
UDG Healthcare Limited
UDG Healthcare UK (Holdco) Limited
Mantis Surgical Limited
Mediscope Limited
Barclay (Northern Ireland) Limited
Klondyke Enterprises Limited
Mansett Limited
Network Hospital Services Limited
Robert Smith & Co. (Derry) Limited
Vector Scientific Limited
Intraveno (N.I.) Limited
New Splint Limited
Unitech Equipment Limited
TD Packaging Limited
Ashfield Alliance Limited
Ashfield Healthcare (Ireland) Limited
Dublin Drug (Investments) Limited
Dublin Drug Company Limited
Dublin Drug Public Limited Company
Dugdale Trading Limited
Marker (U.D.) Ireland Limited
Oremelt Company Unlimited Company
Pharmexx Ireland (Sales Solutions) Limited
UDG Healthcare Ayrtons (Dublin) Limited
UDG Healthcare Finance Limited
UDG Healthcare Ireland Limited
UDG Healthcare Nordic Limited
UDG Healthcare Packaging Group Limited
UDG Healthcare Property Holdings Limited
United Care Limited
Aquilant Analytical Sciences Limited
Aquilant Endoscopy Limited
Aquilant Limited
Aquilant Medical (ROI) Limited
Aquilant Nederland B.V.
Aquilant Northern Ireland Limited
Aquilant Pharmaceuticals Limited
Aquilant Scientific (ROI) Limited
UDG Healthcare Specialist Product Services Limited
Alchem Plc
Pemberton Marketing Limited
Magir Limited
UDG Healthcare Distributors Limited
The Health Insurance Authority
Marker International BV
Magna Finance BV
UniDrug Distribution Group Limited

ENDS

Enquiries:

Peter Dunne                              +353 (0)1 563 4965

Company Secretary

Origin Enterprises plc

Davy (Nominated Adviser)

Anthony Farrell                          + 353 (0)1 614 9993

About Origin Enterprises plc

Origin Enterprises plc is a focused Agri-Services group providing specialist On-Farm Agronomy Services, Digital Agricultural Services and the supply of crop technologies and inputs.  The Group has leading market positions in Ireland, the United Kingdom, Belgium, Brazil, Poland, Romania and Ukraine.  Origin is listed on the ESM and AIM markets of the Irish and London Stock Exchanges.

ESM ticker symbol:       OIZ

AIM ticker symbol:        OGN

Website:                       www.originenterprises.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

STRBUBDGSUGBGIB